LANTERN PHARMA INC: CLINICAL TRIAL MET ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND ESTABLISHED A CLEAR RECOMMENDED PHASE 2 DOSE

Reuters · 3d ago

Please log in to view news